Cytokinetics to Present Key Aficamten Data at ESC Congress 2026
Event summary
- Cytokinetics to present three late-breaking science abstracts at ESC Congress 2026, including primary results from ACACIA-HCM trial for aficamten in non-obstructive hypertrophic cardiomyopathy (HCM).
- Hot Line presentation of ACACIA-HCM results scheduled for August 28, 2026, with additional presentations on August 29, 2026.
- Company to host investor event at ESC Congress to discuss late-breaking science presentations.
- Aficamten is already approved for obstructive HCM; Cytokinetics aims to expand indication to non-obstructive HCM based on ACACIA-HCM results.
The big picture
Cytokinetics is positioning aficamten as a potential cornerstone therapy for both obstructive and non-obstructive HCM, a strategic move that could significantly expand its addressable market. The ESC Congress presentations will be critical in shaping investor expectations around the drug's regulatory and commercial prospects. Success in non-obstructive HCM would further solidify Cytokinetics' leadership in cardiac myosin inhibitors.
What we're watching
- Regulatory Pathway
- Whether the ACACIA-HCM results will support a successful regulatory filing for aficamten in non-obstructive HCM.
- Market Expansion
- The potential size of the non-obstructive HCM market and Cytokinetics' ability to capture it with aficamten.
- Competitive Dynamics
- How competing therapies or emerging treatments for hypertrophic cardiomyopathy may impact aficamten's market position.